Business Context and Reporting Period
Company: American Shared Hospital Services (ASHS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Overview: ASHS provides Gamma Knife radiosurgery units and radiation therapy equipment to medical centers. As of September 30, 2010, the company operated 19 Gamma Knife units across the United States. The company also holds a significant investment in Still River Systems, Inc., a developer of proton beam radiation therapy (PBRT) systems.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 |
|---|---|---|
| Medical Services Revenue | $4,280,000 | $12,523,000 |
| Gross Margin | $1,845,000 (43.1%) | $5,294,000 (42.3%) |
| Operating Income | $196,000 | $517,000 |
| Net Income (Consolidated) | $204,000 | $555,000 |
| Net Income Attributable to ASHS | $6,000 | $17,000 |
| Cash and Cash Equivalents | $1,091,000 | $1,091,000 (Balance Sheet) |
| Net Cash from Operating Activities | N/A | $4,727,000 |
| Total Debt (Current + Long-Term) | $13,153,000 | $13,153,000 (Balance Sheet) |
| Line of Credit Utilization | $8,500,000 | $8,500,000 |
Material Changes vs. Prior Period
- Revenue: Revenue increased 9% ($354,000) for the three-month period compared to the prior year, driven by higher Gamma Knife procedure volumes at upgraded sites. For the nine-month period, revenue decreased slightly by 1.2% ($153,000) due to a shift in volume to sites with lower payment rates, despite a 5% increase in overall procedure volume.
- Costs: Total costs of revenue increased for the quarter but decreased for the nine-month period. Depreciation and amortization expenses declined significantly ($433,000 for nine months) due to assets reaching salvage value and contract extensions.
- Expenses: Selling and administrative expenses increased by 25% ($216,000) for the quarter and 13% ($365,000) for the nine months, primarily due to higher legal, accounting, and travel costs related to new business development.
- Transaction Costs: Transaction costs were $0 for the current periods, compared to $342,000 in the prior nine-month period, as negotiations regarding the sale of the company's interest in GK Financing were terminated in 2009.
- Net Income Attributable to ASHS: Net income attributable to the parent company was minimal ($6,000 for the quarter; $17,000 for nine months) because the majority of consolidated net income ($198,000 and $538,000 respectively) was attributable to the non-controlling interest in the GK Financing subsidiary.
Outlook, Risks, and Contingencies
- Capital Commitments: The company has total remaining commitments of approximately $40,000,000 for equipment purchases, including three Monarch250 proton beam systems from Still River, a Gamma Knife Perfexion unit, and an LGK Model 4 unit.
- Financing Risks: Management notes that obtaining financing for these projects has become more difficult due to the economic downturn. Financing for the PBRT systems is contingent upon Still River obtaining FDA approval, which is not guaranteed.
- Investment Impairment: ASHS holds a $2,617,000 investment in Still River Systems. While a Series D financing round in 2009 resulted in an unrealized loss of approximately $1.2 million, management considers this impairment temporary and intends to hold the investment.
- Liquidity: The company maintains a $9,000,000 line of credit, of which $8,500,000 was drawn as of September 30, 2010. Management believes cash flow from operations is adequate to meet scheduled debt and lease obligations for the next 12 months.
- Regulatory Risk: The commercial viability of the Still River PBRT system depends on FDA approval, with patient treatment anticipated to begin by late 2011.
Investor Verification Checklist
- Non-Controlling Interest Impact: Verify the extent to which consolidated net income is attributable to the non-controlling interest (19% of GK Financing), as this significantly reduces earnings available to common shareholders.
- Financing Availability: Assess the company's ability to secure the necessary financing for the $40 million in equipment commitments, particularly given the reliance on future FDA approval for the Still River systems.
- Still River Investment Status: Monitor the progress of Still River Systems toward FDA approval and the potential for the "temporary" impairment of the $2.6 million investment to become permanent.
- Revenue Mix: Analyze the shift in procedure volume toward sites with lower payment rates and its long-term impact on gross margins.
- Debt Obligations: Review the schedule of upcoming principal and interest payments ($4.66 million debt and $4.29 million capital leases due in the next 12 months) against projected cash flows.